ESMO 2026 | Professor Wei Xu: From Tumor Shrinkage to Surgery—Exploring a New Neoadjuvant Treatment Strategy for Head and Neck Squamous Cell Carcinoma with Iparomlimab, Tovoricimab, and Chemotherapy
Neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) must achieve tumor regression and improve the likelihood of surgery while minimizing the impact on organ function and quality of life. At the 2026 European Society for Medical Oncology (ESMO) Congress, preliminary results were reported from an exploratory study evaluating neoadjuvant iparomlimab and tovoricimab (hereafter referred to as the “combination antibody regimen”) plus nab-paclitaxel and nedaplatin. As of April 2026, 12 patients had been enrolled. The cohort included a relatively high proportion of patients with hypopharyngeal cancer, and most patients had a PD-L1 combined positive score (CPS) of less than 20. The study reported high objective response and pathological response rates. However, this was a small, single-arm exploratory study, and the findings require validation through controlled studies and long-term follow-up. Oncology Frontier interviewed Professor Wei Xu about the study design, interpretation of pathological response, appropriate patient populations, and functional outcomes.







